Ziprax

Quick links to important sections

Ziprax

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ziprax

Quick Facts

Property Description
Active Ingredient Cefixime (INN)
Form Tablets, capsules, oral suspension
Pharmacological Class Third-generation cephalosporin antibiotic
Common Use Treating bacterial infections
Origin Semisynthetic

Cefixime and Its Pharmacological Identity

Ziprax is a prescription-only antibacterial agent designated for the management of infections caused by susceptible bacteria. Its active component is Cefixime, which places it in the specialized group of third-generation cephalosporin antibiotics. Cefixime's classification is clinically recognized for its high resistance to many common bacterial enzymes, distinguishing it from earlier-generation penicillins and cephalosporins. Cefixime is used for the oral treatment of bacterial infections in both adults and children, serving as a treatment option for various conditions. The general therapeutic purpose of this medication is to help the body overcome and eliminate the bacterial population responsible for causing an illness.


Composition, Origin, and Available Forms

The medication contains only the active substance, Cefixime (INN), making it a single-active-ingredient product, and its origin is chemically defined as semisynthetic. Cefixime is characterized by its bactericidal mechanism and its classification as a third-generation antibiotic. Ziprax is prepared in several dosage forms suitable for oral administration, including conventional tablets, capsules, and a powder for oral suspension (often referred to as dry syrup). The availability of the dry syrup formulation, a key differentiating factor, facilitates accurate dosing and easier oral administration for paediatric patients.


How Cefixime Works Against Bacteria (High-Level Principle)

Cefixime functions through a bactericidal action, which means it actively kills the target bacteria, rather than merely slowing their reproduction. The primary mechanism involves the drug interfering with the process bacteria use to construct and repair their cell wall, which is essential for their structural integrity and survival. This structural compromise leads to the death of the bacterial cells, providing the benefit of rapid and effective clearance of the infection in cases such as common respiratory or urinary tract infections.

Regulatory References

  1. (MedlinePlus)

What side effects are possible with Ziprax?

Possible Side Effects and Safety Information

The safety profile of Ziprax (Cefixime) is defined by official regulatory documents which classify potential adverse effects according to the physiological system involved and their frequency of occurrence. The most commonly reported effects primarily affect the gastrointestinal system.


Official Frequency Classification

Classification Examples of Documented Adverse Reactions
Very Common Diarrhea, loose or frequent stools.
Common Nausea, abdominal pain, flatulence.
Uncommon Headache, skin rash.
Rare/Very Rare Vertigo, angioedema, acute renal failure, severe skin reactions.
Frequency Not Known Convulsions, encephalopathy, hemolytic anemia, prolonged prothrombin time.

Serious Adverse Reactions and Safety Constraints

The official label lists several serious adverse reactions, which, though rare, are clinically significant. These include severe, life-threatening anaphylactic or anaphylactoid reactions and Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Furthermore, severe gastrointestinal issues like pseudomembranous colitis (C. difficile-associated diarrhea) are also documented.

Safety notes specify that caution is advised for individuals with a history of penicillin hypersensitivity due to documented cross-allergenicity. Individuals with impaired renal function are recognized as a high-risk population for neurological adverse effects, including encephalopathy. Prolonged use is noted to increase the risk of superinfection by non-susceptible organisms. Safety has not been established for infants under six months of age.

Overdose and Emergency Response

Overdose and when to seek help

This information reflects the official guidance from government regulatory bodies regarding Cefixime (Ziprax) overexposure.

Overdosage primarily presents with adverse effects similar to those seen at therapeutic doses, such as gastrointestinal symptoms (diarrhea, nausea, and vomiting).


Documented Risks and Emergency Action

Area of Concern Official Regulatory Statement
Severe CNS Manifestations The Central Nervous System (CNS) is the primary concern, with risks of seizures and encephalopathy documented following high exposure.
Antidote Availability No specific antidote is known for Cefixime toxicity, necessitating management be focused on supportive care.
Elimination Constraints The drug is not removed in significant quantities by hemodialysis or peritoneal dialysis, limiting the effectiveness of these procedures.
Population Risk Patients with impaired renal function are at a significantly increased risk for CNS adverse events due to reduced drug clearance.

When Immediate Medical Help is Required

Urgent medical attention must be sought immediately for any suspected overdose. This is mandatory, especially if severe neurological symptoms (such as seizures, pronounced confusion, or altered consciousness) are observed. Management should include general symptomatic and supportive treatment, with potential consideration for gastric lavage, as mandated by official overdose protocols. Close clinical observation and hospital monitoring may be required.

Therapeutic Uses of Ziprax

Quick Facts: Uses of Ziprax

  • Respiratory Management: Used for infections of the lungs and airways, such as bronchitis and pneumonia.
  • Ear, Nose, and Throat: Helps manage conditions like otitis media (middle ear infection), pharyngitis, and tonsillitis.
  • Urinary Tract: Employed in the therapeutic management of uncomplicated urinary tract infections (UTIs) and kidney infections.
  • Specific Infections: Indicated for certain cases of uncomplicated gonorrhea.

Ziprax is a prescribed medication used for the therapeutic management of various bacterial infections in adults and pediatric patients aged six months and older. The treatment is intended to address conditions caused by susceptible bacteria.

The medication is employed to resolve symptoms associated with bacterial infections of the respiratory system, including acute exacerbations of chronic bronchitis and pneumonia. It is also utilized in managing infections of the ear, such as otitis media, and certain throat infections like tonsillitis and pharyngitis.

Furthermore, Ziprax supports the resolution of bacterial infections affecting the urinary system, including uncomplicated urinary tract infections. It is also indicated for the treatment of uncomplicated gonorrhea (cervical/urethral). This agent is used for infections that are confirmed or highly suspected to be bacterial.

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed: Ziprax is approved for use in adults and pediatric patients aged six months and older. Older adults are also eligible, but their renal function should be assessed.

Populations for whom use is contraindicated: Use is strictly contraindicated for any patient with a known allergy or hypersensitivity to Cefixime or any antibiotic in the cephalosporin class. It is also prohibited for individuals with a history of immediate or severe allergic reactions to penicillins or other beta-lactam drugs due to the risk of cross-hypersensitivity.


Age and Condition-Based Restrictions

Age-related eligibility rules: The safety and efficacy have not been established in infants under six months of age, making them ineligible for treatment. Children weighing more than 45 kg or older than 12 years are generally treated with the standard adult dose.

Condition-specific eligibility rules: Patients with severe renal impairment require a mandatory dose adjustment as defined in regulatory labeling. Caution is advised for patients with a history of gastrointestinal disease, such as colitis.

Pregnancy and lactation eligibility status: For pregnant women, use is generally not recommended by some regulators, while others assign it to Pregnancy Category B (use if clearly needed). Nursing mothers should consider temporarily discontinuing breastfeeding during treatment.

What should I know about interactions with other medicines?

The official regulatory profile for Ziprax (Cefixime) is defined by several pharmacokinetic and pharmacodynamic interactions with specific medicinal product categories.

Pharmacodynamic and Restriction Interactions

Co-administration with coumarin anticoagulants, such as Warfarin, is associated with reports of a fall in prothrombin activity and prolonged prothrombin time (INR). This effect warrants monitoring, particularly in the elderly or those with hepatic or renal impairment. A documented risk of additive impairment of renal function exists when Cefixime is given with other nephrotoxic agents like aminoglycoside antibiotics and strong-acting loop diuretics such as Furosemide. This nephrotoxicity risk is a heightened concern for patients with existing severe renal function disorders. Additionally, the co-use of agents that inhibit intestinal peristalsis is a contraindication if Cefixime use is associated with colitis.

Exposure-Modifying Interactions

A pharmacokinetic interaction is documented with Nifedipine, a calcium channel blocker, which is officially stated to increase Cefixime's total bioavailability. Conversely, co-administration has been reported to cause elevated Carbamazepine levels and may also reduce the efficacy of oral contraceptives. While the drug can be taken with or without food, food intake is documented to slow the rate of absorption; however, the overall amount absorbed is minimally affected. No major interaction is officially observed with alcohol.

Mechanism of Action

Ziprax inhibits the RANKL (Receptor Activator of Nuclear Factor kappa B Ligand)– RANK interaction, which is a required signaling mechanism for osteoclast precursor survival, proliferation, and differentiation. This targeted action interrupts the communication necessary for the formation and activation of bone-resorbing cells.

By modulating the bone remodeling cycle at this critical juncture, Ziprax influences osteoclast activity and function, leading directly to a decrease in bone resorption. This interruption of osteoclastogenesis is a direct molecular consequence of RANKL- RANK inhibition.

The resulting physiological effect is a sustained and measurable alteration in bone turnover rates. This mechanism shifts the balance of the bone remodeling unit toward the osteoblast action relative to the osteoclast action across the skeletal system.

Dosage and Administration Information

How Ziprax is Used: Administration Overview

Ziprax (Cefixime) is a prescription antibacterial agent. The use of this medication is characterized by parameters outlining the route, standard dosage, and administration conditions. This section describes the general framework for the use of Ziprax.


Administration Parameters

Administration Scope Parameters
Route of Administration Exclusively oral administration via tablets, capsules, or reconstituted oral suspension.
Standard Adult Dose 400 mg per day; may be administered as a single daily dose or divided into two doses of 200 mg every 12 hours.
Pediatric Dosing Children over 6 months receive a weight-based dose, typically 8 mg/ kg/ day, administered as a single dose or in two divided doses.
Timing Relative to Meals May be taken with or without food.
Typical Duration Ranges from 7 to 14 days, depending on the infection. Uncomplicated gonorrhea involves a single 400 mg dose.

Administration Requirements and Special Conditions

Preparation and Handling:

Ziprax powder for oral suspension is reconstituted (mixed with water) by a pharmacist or dispenser. The suspension is shaken well immediately before measuring each dose. Once prepared, the suspension is discarded after 14 days to ensure potency, even if refrigerated. Chewable tablets are chewed or crushed before swallowing.

Dosage Adjustments:

Dosage adjustments are utilized for adult patients with impaired renal function when creatinine clearance (CrCl) is below 60 mL/min. No specific adjustment is required for older adults if renal function is normal.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Ziprax

This section provides a summary of the clinical research, trial designs, and findings that have studied Ziprax (Cefixime) for its approved uses. The evidence highlights what is known and what is still uncertain, reflecting the group patterns observed in research, but research does not determine whether an individual will respond similarly.


Research Evidence for Acute Otitis Media (AOM) and Other Ear/Throat Infections

Research for conditions like AOM, which is a condition associated with acute or disruptive episodes in children, was evaluated in Randomized Controlled Trials (RCTs) and comparative studies. These studies primarily enroll infants and children and were designed to examine short-term outcomes related to physical discomfort, such as measured changes in ear symptoms, and also measure the bacteriologic eradication rate of the causative organisms.

For AOM specifically, regulatory summaries indicate that some studies noted that the measured outcomes in cases involving certain specific bacteria may vary when compared to the measurements observed with other study treatments.

Studies Focused on Tonsillitis and Pharyngitis

Research exploring tonsillitis and pharyngitis was evaluated in comparative clinical studies. The primary focus of these trials was measuring the bacteriologic eradication rate of S. pyogenes from the throat. Regulatory summaries indicate that the role of Cefixime was studied for its association with rare, long-term complications, such as acute rheumatic fever, and research exploring this aspect is limited.


Research Evidence for Uncomplicated Urinary Tract Infections (UTIs)

The evidence base for treating conditions associated with acute or disruptive episodes like uncomplicated UTIs is grounded in Randomized, Prospective Trials and Comparative Studies. These trials research examined outcomes like Microbiological Eradication (measured results related to a sterile urine culture) and Clinical Efficacy (resolution of symptoms, which are outcomes related to systemic or functional imbalance) in adult women.

Findings describe patterns observed in these studies where the resolution of urinary symptoms was tracked alongside measured changes in the presence of bacteria. However, a critical area of ongoing surveillance and research is the changing susceptibility of bacteria. The increasing prevalence of highly resistant bacteria means that local evidence highlights what is known—and what is still uncertain—about the consistent efficacy against evolving resistance patterns.


Long-Term Studies and Durability of Response

Available research was studied for short-term follow-up, typically measuring outcomes describing episodic or acute changes (e.g., 10 to 30 days later). Studies explore short-term changes but there is limited information for long-term outcomes that fully characterize the durability of the response or the frequency of relapse over many months or years. Long-term maintenance data are not fully established across the entire patient population.


What is Still Uncertain or Under Surveillance

Ongoing public health monitoring is continuously researching and tracking antimicrobial resistance patterns. This surveillance is essential because bacterial populations change over time, and the patterns of measured change can be influenced by these shifts. Research exploring Cefixime's role in the prevention of long-term complications from pharyngitis is an area where data are still emerging and specific research is needed. Furthermore, sample sizes were modest in some comparative trials, meaning the results apply only to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Ziprax (FAQ)

Q: Is Ziprax the same kind of medicine as amoxicillin?

A: No, official product information classifies Ziprax ( Cefixime) as a third-generation cephalosporin antibiotic, which belongs to a different drug class from penicillins (like amoxicillin). Regulatory documents caution that cross-hypersensitivity among beta-lactam antibiotics is documented, which is a key consideration for individuals with a penicillin allergy.


Q: Are there any common foods that interact with Ziprax?

A: Official information states that Ziprax can be taken with or without food. While consuming food may cause the medication to be absorbed more slowly, the total amount of medicine your body takes in is not significantly affected. No specific food or food groups are required to be avoided based on label information.


Q: What is the safety profile of Ziprax for children?

A: Regulatory documents indicate that Ziprax is approved for use in pediatric patients aged six months and older. The safety and effectiveness of the medication have not been established in infants under six months of age, meaning it is not used in that younger population.


Q: What is the difference between Ziprax and similar prescription drugs?

A: Ziprax's active ingredient, Cefixime, is classified as a third-generation cephalosporin antibiotic. Regulatory classification suggests it has certain features, such as increased stability against some bacterial enzymes, compared to earlier-generation beta-lactam drugs.


Q: What are the major warnings listed for Ziprax?

A: Official labels list several major warnings, including the potential for severe allergic reactions and serious intestinal issues like Clostridium difficile-associated diarrhea ( CDAD). Other warnings relate to the need for dose adjustment in patients with kidney impairment and the possibility of effects on blood clotting ( prolonged prothrombin time).


Q: Is Ziprax safe to use during pregnancy? (Descriptive query)

A: Official guidance on use during pregnancy varies depending on the regulatory body. Some regulators do not recommend its use during pregnancy, while others categorize it as Pregnancy Category B, suggesting that the decision for use should be made after a careful assessment of the risks and benefits.


Q: Can Ziprax be crushed or split if a patient has trouble swallowing pills? (General query)

A: Official administration instructions state that the chewable tablet form must be chewed or crushed before swallowing. For standard tablets, official labeling indicates they may be split or cut if they have a score line. Official instructions generally require that capsules be swallowed whole.


Q: How does the action of Ziprax differ from older treatments for the same condition?

A: Ziprax is an antibacterial agent that works by killing bacteria ( bactericidal action) through inhibiting the synthesis of the bacterial cell wall. The third-generation status provides a different spectrum of activity compared to some older treatments.


Q: Does Ziprax work immediately, or does it take time to build up in the body?

A: The drug begins its bactericidal action by interfering with bacterial cell wall synthesis immediately after absorption. However, measurable peak concentration in the blood is typically reached 3 to 4 hours after a dose is administered.


Q: Are there any specific organs Ziprax is known to primarily affect?

A: Side effects are most commonly reported in the gastrointestinal system, resulting in issues like diarrhea and nausea. Regulatory warnings also describe potential effects on the kidneys ( acute renal failure) and, rarely, the central nervous system ( seizures or encephalopathy).


Q: Can Ziprax cause fatigue or tiredness?

A: While fatigue or tiredness are not listed as common or frequent side effects in the core regulatory tables for Ziprax, general adverse reaction reports for the cephalosporin drug class have included unusual weakness or tiredness. Any unusual or persistent symptoms should be discussed with a healthcare professional.


Q: How long does it usually take to feel the effects of Ziprax?

A: As a bactericidal medicine, Ziprax begins acting promptly to eliminate bacteria. However, the time to noticeable improvement is highly variable and depends on the specific type and severity of the infection.


Q: What should I do if I miss a dose of Ziprax? (General query, non-directive)

A: Official product information advises that a missed dose is generally taken as soon as remembered. However, if it is close to the time for the next scheduled dose, the missed dose is typically skipped to continue the regular schedule. Regulatory guidance advises against taking a double dose.


Q: How long does Ziprax stay in your system after stopping treatment?

A: Official pharmacokinetic data shows that the half-life of Cefixime (the time it takes for half the drug to be eliminated from the body) is typically between 3 and 4 hours. The drug is progressively cleared from the system over a period of time following the final dose.


Q: Can Ziprax be taken with over-the-counter pain relievers like ibuprofen?

A: Official drug interaction tables do not list ibuprofen (a common NSAID pain reliever) as having a major or moderate interaction with Cefixime. As with any medicine, any planned use of concurrent medications should be discussed with a healthcare professional.


Q: Is it true that Ziprax can affect liver function?

A: Official regulatory documents report that transient elevations in liver enzymes and hepatic dysfunction have been reported as adverse reactions. These effects include hepatitis and jaundice in some documented cases.


Q: Does Ziprax cause drowsiness, making it difficult to drive?

A: Regulatory information lists dizziness and vertigo as uncommon side effects. Furthermore, neurological adverse effects, including seizures, have been reported, particularly in individuals with kidney impairment who did not receive a dose adjustment.


Q: Why is a full course of Ziprax typically prescribed?

A: The full prescribed course of the medicine is recommended to be completed, even with early improvement of symptoms. Completing the course is important to minimize the risk of incomplete treatment or developing drug-resistant bacteria.


Q: Can Ziprax affect the results of certain lab tests?

A: Yes, official labeling states that Ziprax may cause a false-positive result for glucose in the urine when tested using certain methods ( copper reduction tests). It may also result in a false-positive direct Coombs test.


Q: What are the symptoms of an overdose of Ziprax?

A: Regulatory documents state that there is no specific antidote available for Cefixime overdose. Official labeling notes that seizures may occur with overdose, especially in patients with existing kidney impairment.


Q: What does official guidance say about taking Ziprax with milk products?

A: Official guidance on the use of Ziprax indicates that the medication may be taken with or without food. There is no specific warning or official guidance recommending against the consumption of milk products during treatment.


Q: Can Ziprax make someone more sensitive to sunlight?

A: Photosensitivity (increased sensitivity to sunlight) is not explicitly listed in the core regulatory adverse reaction tables for Ziprax. However, severe skin reactions ( rash, Stevens-Johnson syndrome) are documented as potential side effects.


Q: Is it normal to feel a metallic taste after taking Ziprax?

A: Taste perversion ( dysgeusia) or a metallic taste is not listed as a common or frequent side effect in the official Cefixime labeling. Any unusual or concerning symptoms should be discussed with a healthcare professional.

How should Ziprax be stored and disposed of?

Storage and Disposal Requirements

Ziprax (Cefixime) storage and disposal instructions are based on official regulatory labeling to maintain drug potency and ensure household safety.

Official Storage Conditions

Dosage Form Temperature Requirement Stability Constraint
Tablets/Capsules & Powder Controlled Room Temperature (20 C–25 C) Protect from excess moisture, heat, and freezing.
Reconstituted Suspension Room temperature or refrigerated Must be discarded after 14 days. Do not freeze.

All forms must be kept in their original, tightly closed container and protected from direct light.

Child Safety and Handling

To prevent accidental poisoning, the medication must be stored out of the sight and reach of children. Always lock safety caps and place the medication in a high, safe location.

Labeled Disposal Rules

Unused or unwanted Ziprax should be disposed of by utilizing a drug take-back program. If a program is unavailable, mix the medicine with an unappealing substance, such as dirt or used coffee grounds, seal the mixture in a plastic bag, and place it in the household trash. Do not flush this medicine down the toilet unless explicitly instructed by the product's official instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ziprax found in:

A-Z Index: